Recce Pharmaceutical CEO James Graham joins Proactive to run through the company’s key focus areas and standout achievements across 2025.
He highlights progress in preclinical efficacy results for R327 including treating ventilator-associated pneumonia, positioning the drug as a potential new class of antibiotic.
Graham discusses licensing, clinical milestones, including a successful Phase 2 study and momentum heading into 2026.
#ReccePharmaceuticals #ProactiveNewsroom #Biotech #Antibiotics #AntiInfectives #ClinicalTrials #ASXBiotech #HealthcareInnovation #R327 #PharmaNews